Tissue Microarray of Hematological Malignancies
- Conditions
- Hematological Malignancies
- Registration Number
- NCT04142372
- Lead Sponsor
- Tampere University Hospital
- Brief Summary
The aim of the study is to create new tools for improving management of patients with hematological malignancies by combining extensive clinical data from patients newly diagnosed with hematological malignancies and innovative laboratory analyses made on available tissue samples in regional biobanks from these patients.
- Detailed Description
Firstly, clinical information is collected on all hematological malignancies diagnosed in our hospital district area retrospectively between the years 2000 and 2019. Clinical outcomes, laboratory results, clinically relevant diagnoses, characteristics defining clinical stage and established prognostic parameters are gathered.
Simultaneously a tissue microarray (TMA) of diagnostic samples is compiled using representative annotated tissue areas. This TMA is used in combination with additional control material to identify prognostic and predictive biomarkers.
A combined microarray dataset of hematological malignancies (Hemap) is utilized to point out genes of possible drug targets, disease specific markers, prognostic markers, or predictive markers.
The clinical datasets and Hemap dataset is ultimately utilized to gain knowledge, new tools for prognostication and diagnostics, and targets for treatment. Artificial intelligence -assisted differential diagnostics will be tested.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 5000
- hematological malignancy/neoplasm
- Non-sufficient data available
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to treatment From the first line treatment up to the end of the study period (April 2019). Best response to the first line treatment for the hematological malignancy, according to malignancy in question, e.g. complete response (CR), stringent complete response (sCR), partial response (PR), very good partial response (VGPR), stable disease (SD), progressive disease (PD), treatment failure, clinical response, hematological response etc.
Event-free survival (EFS) From the first line treatment up to the end of the study period (April 2019). Survival time from the first line treatment for hematological malignancy until any primary event (death, relapse, disease progression/transformation, secondary malignancy, resistant disease etc.), whichever came first, assessed up to the end of the study period (April 2019).
Progression-free survival (PFS) From the first line treatment up to the end of the study period (April 2019). Time from the first line treatment for hematological malignancy until the date of first documented relapse or transformation or death of any cause, whichever came first, assessed up to the end of the study period (April 2019).
Overall survival (OS) From the diagnosis up to the end of the study period (April 2019). Survival time from the diagnosis of hematological malignancy until the date of death of any cause, assessed up to the end of the study period (April 2019).
- Secondary Outcome Measures
Name Time Method Thrombo-embolism From the first line treatment up to the end of the study period (April 2019). Venous thromboembolism
Best response From the first line treatment up to the end of the study period (April 2019). Best response e.g. hematological remission, molecular remission, radiological remission
Disease transformation From the diagnosis up to the end of the study period (April 2019). Hematological malignancy transforms into another malignancy
Adverse effects From the first line treatment up to the end of the study period (April 2019). Treatment-related adverse effects/events
Sepsis or other life-threatening infection From the first line treatment up to the end of the study period (April 2019). Fulminant infection after diagnosis
Time to complete remission From the first line treatment up to the end of the study period (April 2019). Time to complete remission
Time to best response From the first line treatment up to the end of the study period (April 2019). Time to best response e.g. hematological remission, molecular remission, radiological remission
Multiple organ failure From the first line treatment up to the end of the study period (April 2019). Altered organ function in acutely ill patient
ICU admission From the first line treatment up to the end of the study period (April 2019). Admission to intensive care unit
Relapse From the first line treatment up to the end of the study period (April 2019). Relapse after or during the treatment.
Secondary malignancy From the first line treatment up to the end of the study period (April 2019). Secondary malignancy after the diagnosis of hematological malignancy
Complete remission From the first line treatment up to the end of the study period (April 2019). Complete remission after the treatment
Trial Locations
- Locations (1)
Tampere Univerisity Hospital
🇫🇮Tampere, Finland